614 results on '"Schwabl, Philipp"'
Search Results
2. Contrasting genomic epidemiology between sympatric Plasmodium falciparum and Plasmodium vivax populations
3. Clinical course of congestive hepatopathy pre/post heart transplantation
4. Von Willebrand factor processing in patients with advanced chronic liver disease and its relation to portal hypertension and clinical outcome
5. Post-treatment LSM rather than change during treatment predicts decompensation in patients with cACLD after HCV cure
6. Bacterial translocation occurs early in cirrhosis and triggers a selective inflammatory response
7. Austrian consensus on the diagnosis and management of portal hypertension in advanced chronic liver disease (Billroth IV)
8. Transcriptomic signatures of progressive and regressive liver fibrosis and portal hypertension
9. Subcutaneous therapy for portal hypertension: PHIN-214, a partial vasopressin receptor 1A agonist
10. Genomics and spatial surveillance of Chagas disease and American visceral leishmaniasis
11. Alcohol Abstinence Improves Prognosis Across All Stages of Portal Hypertension in Alcohol-Related Cirrhosis
12. Perspectives on environmental heterogeneity and seasonal modulation of stress response in neotropical birds
13. Impact of ammonia levels on outcome in clinically stable outpatients with advanced chronic liver disease
14. SAT-128 Circulating fibronectin levels are linked to endothelial dysfunction, fibrogenesis, and portal hypertension in advanced chronic liver disease
15. WED-089-YI Characterising the hemodynamic and pro-inflammatory profile of a CCl4/LPS-induced acute-on-chronic liver failure (ACLF) rat model
16. THU-540 Characterization of in vivo mouse models of regressive fibrosis and resolving portal hypertension
17. THU-071 Impact of underlying portal hypertension and systemic inflammation on acute-on-chronic liver failure (ACLF) severity and outcome
18. WED-125 Differential regulation of soluble guanylate cyclase signaling during liver fibrosis regression
19. Non-invasive tests for clinically significant portal hypertension after HCV cure
20. Angiopoietin 2 levels decrease after HCV-cure and reflect the evolution of portal hypertension
21. Decreasing von Willebrand Factor Levels Upon Nonselective Beta Blocker Therapy Indicate a Decreased Risk of Further Decompensation, Acute-on-chronic Liver Failure, and Death
22. The prognostic value of HVPG-response to non-selective beta-blockers in patients with NASH cirrhosis and varices
23. Splenectomy ameliorates portal pressure and anemia in animal models of cirrhotic and non-cirrhotic portal hypertension
24. Clinical Course of Porto-Sinusoidal Vascular Disease Is Distinct From Idiopathic Noncirrhotic Portal Hypertension
25. Distinct prognostic value of different portal hypertension-associated features in patients with primary biliary cholangitis
26. Nuclear receptors in liver fibrosis
27. Subcutaneous Administration of a Monoclonal Antibody to Prevent Malaria
28. Contrasting genomic epidemiology between sympatricPlasmodium falciparumandPlasmodium vivaxpopulations
29. The differential activation of cardiovascular hormones across distinct stages of portal hypertension predicts clinical outcomes
30. Placental growth factor levels neither reflect severity of portal hypertension nor portal-hypertensive gastropathy in patients with advanced chronic liver disease
31. Comparison of the diagnostic quality of aspiration and core-biopsy needles for transjugular liver biopsy
32. Direct patient-physician communication via a hepatitis C hotline facilitates treatment initiation in patients with poor adherence
33. Temporal and spatial dynamics of Plasmodium falciparum clonal lineages in Guyana.
34. Temporal and spatial dynamics of Plasmodium falciparum clonal lineages in Guyana
35. Decreased platelet activation predicts hepatic decompensation and mortality in patients with cirrhosis
36. Thromboelastometry in patients with advanced chronic liver disease stratified by severity of portal hypertension
37. Vitamin A levels reflect disease severity and portal hypertension in patients with cirrhosis
38. Colonization and genetic diversification processes of Leishmania infantum in the Americas
39. Performance of Controlled Attenuation Parameter in Patients with Advanced Chronic Liver Disease and Portal Hypertension
40. Transjugular aspiration liver biopsy performed by hepatologists trained in HVPG measurements is safe and provides important diagnostic information
41. Venezuela's humanitarian crisis, resurgence of vector-borne diseases, and implications for spillover in the region
42. Point Shear Wave Elastography for Non-invasive Assessment of Liver Fibrosis in Patients with Viral Hepatitis
43. Resurgence of Vaccine-Preventable Diseases in Venezuela as a Regional Public Health Threat in the Americas
44. Comparison of three cut-offs to diagnose clinically significant portal hypertension by liver stiffness in chronic viral liver diseases: a meta-analysis
45. Re-bleeding rates and survival after early transjugular intrahepatic portosystemic shunt (TIPS) in clinical practice
46. Diabetes impairs the haemodynamic response to non‐selective betablockers in compensated cirrhosis and predisposes to hepatic decompensation
47. Hepatic recompensation according to Baveno VII criteria is linked to a significant survival benefit in decompensated alcohol‐related cirrhosis
48. Correction: Vector mapping and bloodmeal metabarcoding demonstrate risk of urban Chagas disease transmission in Caracas, Venezuela
49. Clinical course of congestive hepatopathy pre/post heart transplantation
50. Systemic inflammation remains a critical determinant of the dynamic component of portal hypertension in abstinent patients with alcohol-related cirrhosis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.